Cargando…
Editorial: Drug Survival: Treatment of Rheumatic Diseases in the Biologic Era
Autores principales: | Di Sanzo, Lorenzo, Scrivo, Rossana, Soriano, Enrique Roberto, Citera, Gustavo, Mysler, Eduardo, Wei, James Cheng-Chung, Ríos, Mario Humberto Cardiel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895950/ https://www.ncbi.nlm.nih.gov/pubmed/35252282 http://dx.doi.org/10.3389/fmed.2022.858817 |
Ejemplares similares
-
Rheumatic Diseases and Obesity: Adipocytokines as Potential Comorbidity Biomarkers for Cardiovascular Diseases
por: Scrivo, Rossana, et al.
Publicado: (2013) -
Incidence Rates of Interstitial Lung Disease Events in Tofacitinib-Treated Rheumatoid Arthritis Patients: Post Hoc Analysis From 21 Clinical Trials
por: Citera, Gustavo, et al.
Publicado: (2021) -
Changes in T cell effector functions over an 8-year period with TNF antagonists in patients with chronic inflammatory rheumatic diseases
por: Sauzullo, Ilaria, et al.
Publicado: (2018) -
Prevalence of periprosthetic osteolysis after total hip replacement in patients with rheumatic diseases
por: Perez Alamino, Rodolfo, et al.
Publicado: (2012) -
Beyond Rheumatoid Arthritis Evaluation: What are We Missing?
por: Espinoza, Gianna, et al.
Publicado: (2021)